Market Overview

Agilent Announces SureSelect XT HS2 RNA Reagent Kit, a Library Prep and Target Enrichment Solution for RNA-Seq


Streamlined solution for RNA and DNA-seq to simplify clinical NGS

Agilent Technologies Inc. (NYSE:A) today announced the release of the SureSelect XT HS2 RNA Reagent Kit. This solution features a modular design that enables a simple and parallel approach for both RNA and DNA samples, allowing customers to streamline and consolidate their workflow without losing time optimizing different kits for different sample types. It marks the latest development in Agilent's ongoing effort to improve NGS applications and workflows, leveraging the performance and versatility of XT HS2 chemistry.

"Agilent has innovated library prep and target enrichment for RNA and DNA into a parallel sequencing workflow," says Kevin Meldrum, vice president, and general manager of Agilent's Genomics Division. "The new streamlined solution will help simplify the technician's workday and provides fast turnaround time of only 1–2 days for library preparation regardless of sample type."

The SureSelect XT HS2 RNA Reagent Kit expands the NGS applications of the XT HS2 chemistry, allowing customers to accurately profile gene expression and detect RNA fusions using low-input FFPE samples. The addition of this kit distinguishes Agilent as the leading vendor in the industry to offer a complete end-to-end NGS sample prep solution from sample QC, library prep and target enrichment, automation, and data analysis, backed by a simple and easy one-stop-shop ordering and support experience.

The kit is anticipated to significantly improve efficiency, especially in labs processing both DNA and RNA samples for NGS applications. "This new solution delivers fast turnaround time so we can spend less time on wet lab work and focus more on results," says Georges A. Belderbos, head of marketing and sales for NEO New Oncology GmbH. "FFPE compatibility and a parallel workflow to the XT HS2 DNA kit simplified implementation so we could start detecting RNA fusions quickly."

SureSelect XT HS2 RNA supports 384 unique dual sample indexes (UDIs) and allows customers to multiplex hundreds of samples in one sequencing run without worrying about index hopping. It features molecular barcodes, for more efficient deduplication of sequencing reads and more accurate gene expression analysis. SureSelect XT HS2 RNA may be purchased with Ampure and Streptavidin beads as part of a complete kit.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at